Search

Search Constraints

You searched for: Author/Creator Pohlman, Brad L.

Search Results

1. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long‐term outcomes. (8th March 2016)

2. Dual institution experience of nodal marginal zone lymphoma reveals excellent long‐term outcomes in the rituximab era. (22nd July 2016)

4. Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma. Issue 1 (January 2015)

5. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era. Issue 7 (9th August 2017)